CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Blueprint Medicines Corporation - BPMC CFD

104.02
0.85%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.35
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 104.91
Open 103.93
1-Year Change 63.16%
Day's Range 102.3 - 105.11
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 20, 2024 104.91 1.43 1.38% 103.48 106.33 102.92
Jun 18, 2024 106.48 3.88 3.78% 102.60 106.76 101.84
Jun 17, 2024 103.50 -0.13 -0.13% 103.63 107.27 102.33
Jun 14, 2024 105.31 3.17 3.10% 102.14 106.43 102.14
Jun 13, 2024 106.16 0.61 0.58% 105.55 107.87 104.79
Jun 12, 2024 105.71 -0.85 -0.80% 106.56 108.45 103.48
Jun 11, 2024 105.23 2.27 2.20% 102.96 105.66 101.08
Jun 10, 2024 103.87 2.94 2.91% 100.93 104.19 100.15
Jun 7, 2024 103.21 2.25 2.23% 100.96 105.88 100.96
Jun 6, 2024 104.15 -0.79 -0.75% 104.94 105.22 103.16
Jun 5, 2024 105.47 4.47 4.43% 101.00 106.29 99.62
Jun 4, 2024 101.35 -3.39 -3.24% 104.74 104.79 101.27
Jun 3, 2024 104.68 -0.95 -0.90% 105.63 108.22 101.58
May 31, 2024 105.47 -1.41 -1.32% 106.88 107.98 103.87
May 30, 2024 106.19 5.20 5.15% 100.99 106.59 100.47
May 29, 2024 100.37 2.44 2.49% 97.93 101.45 97.93
May 28, 2024 102.14 -0.33 -0.32% 102.47 103.39 100.56
May 24, 2024 102.69 2.60 2.60% 100.09 105.85 100.09
May 23, 2024 101.71 -1.22 -1.19% 102.93 104.01 100.97
May 22, 2024 102.56 0.59 0.58% 101.97 103.58 101.17

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Blueprint Medicines Corporation Company profile

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a global precision therapy company that is inventing medicines for people with cancer and blood disorders. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The Company is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Blueprint Medicines Corp revenues decreased 77% to $180.1M. Net loss totaled $644.1M vs. income of $313.9M. Revenues reflect Collaboration revenue decrease of 84% to $122.4M. Net loss reflects Other Research and development increase of 91% to $561.4M (expense), Selling/General/Admin Expense increase of 24% to $143.3M (expense), Stock-based Compensation in SGA increase of 24% to $52M (expense).

Industry: Biotechnology & Medical Research (NEC)

45 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US

News

Bank of England preview: no rate cut just yet despite CPI returning to 2%

The Bank of England (BoE) is widely expected to keep rates unchanged when it meets on Thursday. Analyst Daniela Harthorn looks at what this could mean

12:45, 18 June 2024

RBA Meeting Preview: No change to policy expected, markets look for fresh guidance

The Reserve Bank of Australia is expected to keep interest rates unchanged at 4.35% when it meets on Tuesday, June 18th, 2024, at 2:30 PM (AEST).

13:17, 17 June 2024

FOMC Decision Review: Rates unchanged as central bank raises inflation and interest rate forecasts

The FOMC left Federal Funds Rate unchanged at a target range of 5.25 to 5.50%.

10:55, 17 June 2024

Bank of Japan Preview: Markets look for guidance from BOJ about timing of next hike

The Bank of Japan meets on Friday, 14th of June, 2024. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

11:05, 12 June 2024

FOMC preview: Still expecting three rate cuts in 2024?

The Federal Reserve is expected to keep its policy unchanged on Wednesday – data from Reuters shows a 99% chance of no change. Last week’s 25-basis-point rate cut from the ECB has done nothing to change market expectations, and why should it?

08:20, 11 June 2024

US Non-Farm Payrolls Preview: Forecasts point to a stable labour market

US labour market conditions are expected to have remained stable in May. The latest Non-Farm Payrolls data will be released on Friday, June 7th, 2024, and will provide a health check on the US jobs market.

10:09, 5 June 2024

AUD/USD analysis: Focus turns to GDP data after unexpected CPI rise

Higher-than-expected monthly CPI data watered down expectations for RBA interest rate cuts in 2024; the markets will now shift attention to quarterly GDP data on Wednesday, June 5.

15:57, 4 June 2024

People also watch

BTC/USD

64,282.80 Price
-1.260% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

19,738.30 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,507.72 Price
-0.510% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,322.11 Price
-1.630% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 21:00 (UTC)
Spread 0.80

Still looking for a broker you can trust?

Join the 620,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading